

**APPROVED**

**By Jean Gildner at 3:24 pm, Dec 12, 2016**

**From:** [Margarita Aguilera](#)  
**To:** [Gildner, Jean](#)  
**Cc:** [Lorien Armour](#)  
**Subject:** BLA125603 Information Request - November 2, 2016  
**Date:** Thursday, November 03, 2016 4:48:23 PM  
**Attachments:** [image001.png](#)  
[Information Request Matricel Supplier Qualification Final 3 November 2016.pdf](#)

---

Dear Jean,

Enclosed please find Vericel' s response to the information request below regarding supplier qualification.

Thanks in advance for confirming receipt.

Best regards,  
Margarita

Margarita Aguilera, M.Sc.  
Senior Regulatory Consultant – Vericel Corporation  
64 Sidney Street  
Cambridge, MA 02139  
[maguilera@vcel.com](mailto:maguilera@vcel.com);  
Telephone: (617) 588-5661  
Mobile: (224) 659-2129  
Facsimile: (734) 239-7401

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.

---

**From:** Gildner, Jean [mailto:Jean.Gildner@fda.hhs.gov]  
**Sent:** Wednesday, November 02, 2016 9:08 AM  
**To:** Margarita Aguilera  
**Subject:** RE: BLA125603 Information Request

Dear Margarita,

Please see the following IR request:

***Regarding supplier qualification describe in the BLA (section 3.2.S.2, 3.1 “supplier qualification”), Please provides the most recent vendor audit (supplier qualification) that was performed for the Matricel facility and brief summary of Matricel supplier***

***qualification. If Vendor audit was not performed, Please provide your rational for not conducting vendor audit and propose timeline.***

***(Please ask Vericel to response by this Friday).***

Please acknowledge receipt of this request.

Sincerely, Jean

*Jean F. Gildner* MSHS, MT (ASCP), CQA (ASQ)

**Regulatory Project Manager  
Center for Biologics Evaluation and Research  
Office of Tissues and Advanced Therapies  
U.S. Food and Drug Administration**

Tel: 240-402-8296

[jean.gildner@fda.hhs.gov](mailto:jean.gildner@fda.hhs.gov)



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.